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Betapapillomaviruses have been linked to the develop-
ment of nonmelanoma skin cancers. A great diversity of 
these viruses in skin specimens requires the use of sensi-
tive and reliable detection methods. There are currently 
no standardized assays for diagnostic purposes. A com-
bination of several molecular methods has great practi-
cal significance and gives the opportunity to broaden 
the spectrum of detected Beta-HPV types. In the present 
study, different molecular methods for Beta-HPVs de-
tection and genotyping were used: PCRs with different 
sets of primers, PCR followed by reverse hybridization 
and direct sequencing of PCR amplimers; all performed 
in skin biopsies from lesions and perilesional healthy 
area of 118 patients with NMSC or precancerous lesions. 
Beta-HPVs were detected in 41% of 261 biopsies exam-
ined. The RHA for 25 types of Beta-HPVs showed a sig-
nificantly higher sensitivity than PCR-based methods 
and allowed to detect 172 genotypes in 86 samples, in-
cluding 39 with multiple infections. The most frequently 
identified types were HPV23, HPV24 and HPV93. HPV5 
and HPV8, considered high-risk carcinogen types, were 
detected only in a small percentage of samples. Direct 
sequencing confirmed the presence of Beta-HPV geno-
types from outside of RHA panel in the analysed biop-
sies. This allowed detecting thirty-two additional geno-
types in 5 samples, that were positive only in RHA with 
the universal probe, which failed to identify the virus 
genotypes. Our findings confirmed the need to apply dif-
ferent methods to detect Beta-HPV infections.
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INTRODUCTION
HPVs that infect cutaneous or mucosal epithelia belong 
to the Papillomaviridae family of DNA viruses. Based on 
their DNA sequence, a phylogenetic tree was generated, 
in which the different HPV types are classified into five 
genera, named with Greek letters: Alpha-, Beta-, Gamma-, 
Mu- and Nupapillomavirus (Tommasino, 2017; Van Doors-
laer et al., 2018). The genus Alphapapillomavirus contains 
many HPV types related to the neoplastic processes in 
the genital tract (Zur Hausen, 2000; Szostek et al., 2008). 
Beta-HPVs have an affinity for the skin. More than 50 
fully sequenced and characterized types of human Be-
ta-HPVs are further subdivided into five different spe-
cies (beta-1 to beta-5) (Van Doorslaer et al., 2018; Gheit, 
2019). The HPV5 and HPV8 types from the beta-1 spe-
cies, previously known as EV-associated types, were first 
identified in warts and skin carcinomas of EV patients 
(Jablonska et al., 1972; de Jong et al., 2018). These two 
types have been very often found in SCC samples ob-
tained from patients with EV and thus could be quali-
fied as high-risk types (carcinogen group 2B) (Bouvard 
et al., 2009; Viarisio et al., 2017). The important role of 
Beta-HPVs in NMSC in non-EV individuals is still be-
ing discussed. Cutaneous HPVs are characterized by a 
great diversity; they are ubiquitous and widespread in 
the general population. The infections can be persistent 
and asymptomatic, often caused by many types of Beta-
HPVs, but the viral load for an individual type can be 
very low (Forslund, 2007; Rollison et al., 2019; Tom-
masino, 2019). Moreover, there are no standardized di-
agnostics assays and one commercially available test for 
genotyping is only used for research purposes. In the 
face of the above facts, early and reliable diagnostics is 
particularly important.
The study of the association between Beta-HPVs 
and NMSC depends on HPV detection and genotyping 
methods (Meyer et al., 2000; Stockfleth et al., 2004). Vari-
ous studies used different diagnostic methods. The lead-
ing assays are those based on molecular techniques, such 
as PCR with different modifications, followed by geno-
typing by sequencing of the PCR products, reverse line 
blotting assay, restriction fragment length polymorphism 
analysis or hybridization with oligonucleotide probes 
(Antonsson et al., 2013; Bouwes Bavinck et al., 2010; 
Brink et al., 2005).
The family of skin-tropic HPVs is very diversified and 
for this reason, several primer sets were described and 
analyzed in previous years, e.g. the consensus degenerate 
CP65/70 and CP66/69, FAP59/64 and FAP6085/6319 
or CP62/71 and CP64/70 for the nPCR (Berkhout et al., 
1995; Berkhout et al., 2000; Forslund et al., 2003) as well 
as the consensus nondegenerate or specific primers (PM 
primers or primers for multiplex PCR) recommended by 
de Koning and others (de Koning et al., 2006) and Gheit 
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and others (Gheit et al., 2007), respectively. With their 
specific amplification conditions, these primers targeted 
different genes of various types of cutaneous HPVs and 
allowed the detection of a wide range of Beta-HPVs. 
Figure 1 shows various attachment sites of the afore-
mentioned primer sets and the size of the amplification 
products obtained by various methods. The main disad-
vantage of the nPCRs introduced above is their limited 
sensitivity to distinct HPV types as well as a possibility 
of contamination associated with nPCR procedures and 
a higher risk of nonspecific cross-reactions (de Koning et 
al., 2006). The introduction of single-type specific prim-
ers (Meyer et al., 2000; Pfister et al., 2003) results in high-
er sensitivity, but encompasses only selected HPV types 
and therefore is very laborious.
The aim of the present study was to determine the 
prevalence of Beta-HPV DNA in patients with NMSC 
or precancerous lesions. Various molecular methods for 
detection of Beta-HPV sequences such as: PCR with 
general and specific primers as well as direct sequenc-
ing of nPCR products and PCR combined with reverse 
hybridization of biotinylated amplicons for genotyping 
of Beta-HPVs were used. These methods were evaluat-
ed for their suitability for the identification of cutaneous 
HPVs in biopsies from changed and unchanged skin. It 
was assumed that the combination of several diagnostic 
tests may give the opportunity to broaden the spectrum 
of detected types. This may be crucial in view of the di-
agnostic difficulties in detecting Beta-HPVs.
MATERIALS AND METHODS
A total of 261 biopsies were collected from 106 pa-
tients with NMSC and 12 patients with precancerous 
skin lesions. Among the individuals with NMSC, there 
were 95 patients with histopathologically confirmed BCC 
and 11 with SCC. Patients were treated between 2006 
and 2016 in the Department of Dermatology, Jagiellon-
ian University Medical College, Krakow, Poland. The 
mean age of patients was 71.7 years (range of 33–96 
years). Men predominated (73/118; 61.9%) in the stud-
ied group.
Biopsies were taken not only from tumours but also 
from perilesional healthy skin of each patient to assess 
the presence of HPVs. In 12 patients, specimens were 
taken from two to three different locations. All samples 
were collected using sterile scalpels and then immersed 
in 0.9% NaCl. They were frozen at -80°C in individual 
Eppendorf tubes and successively tested. The study was 
approved by the Bioethics Committee of the Jagiellonian 
University (KBET/100/B/2006; KBET/214/B/2013; 
KBET/108/B/2014), and informed consent was ob-
tained from each patient.
DNA isolation. DNA was isolated from each spec-
imen using the spin-column method (Genomic Mini 
Test, A&A Biotechnology, Poland) according to the 
manufacturer’s instruction. To determine the presence 
and the quality of human DNA in the samples, the be-
ta-actin gene amplification was performed resulting in a 
307 bp product, according to the procedure described 
earlier (Szostek et al., 2009).
Detection of cutaneous Beta-HPVs by PCR. The 
nPCR method, according to Berkhout et al. (1995), was 
used as the first step for the preliminary examination. 
In this reaction, two pairs of general degenerate prim-
ers CP65-70 (CP65/70 and CP66/69 as external and 
internal, respectively) were used for the detection of 
EV-associated HPVs (HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 
Figure 1. Simplified chart of the size and position of the PCR products in reference to E1, E7 and L1 HPV8 genes location on the DNA 
strand
The size and position of the PCR products for different primers according to Berkhout et al., 1995, 2000; Forslund et al., 2003; de Koning 
et al., 2006; Gheit et al., 2007.
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21, 22, 23, 24, 25, 36, 37, 38, 46, 49). Separate PCR re-
actions with primers specific for HPV5 (Kawase et al., 
1996) and HPV8 (Fuchs et al., 1986) were also applied. 
Fifty ng of genomic DNA was used as the template. All 
amplifications were performed using the S1000 thermal 
cycler (Biorad, USA). For every reaction, negative (water) 
and positive controls were included. The positive con-
trols were obtained by courtesy of Prof. M. Malejczyk 
from the Medical University of Warsaw, Poland. The 
amplified products were analyzed by electrophoresis in 
3% agarose gel and stained with ethidium bromide.
The analytical sensitivity of the nPCR was determined 
by amplification of ten-fold serial dilutions of the posi-
tive control (HPV5).
PCR with RHA. Detection and genotyping of 25 dif-
ferent types (HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 
23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, 96) of 
cutaneous Beta-HPVs from five species was carried out 
with RHA Kit Skin (beta) HPV (Diassay, Rijswijk, The 
Netherlands). This panel included both the EV-associat-
ed and non-EV-associated HPV types. In this method, 
a one-step amplification of a 117-base pair region from 
the E1 gene of Beta-HPVs was applied using the nonde-
generate PM primer set containing a biotin label. Bioti-
nylated amplicons were hybridized with oligonucleotide 
probes immobilized as parallel lines on membrane strips. 
The hybrids formed were visualized in an enzymatic col-
our reaction. Positive (HPV93 plasmid clone) and nega-
tive (water) controls were included in all reactions.
In addition to specific probes, each strip contained a 
mixture of universal HPV probes for the detection of al-
most all Beta-HPVs. Positive results with those universal 
probes without manifestation of specific types indicated 
the presence of other genotypes from the Beta-HPVs 
group. All procedures were performed exactly according 
to the manufacturer’s instructions.
Sequencing. To determine the Beta-HPV types in se-
lected samples, the amplification products derived from 
EV-spectrum nPCR were purified and analyzed by direct 
DNA sequencing performed on the automated 3730 xl 
DNA Analyzer system (Applied Biosystems). The ob-
tained DNA sequences were compared to all available 
HPV sequences stored in the NCBI database by the 
nucleotide-nucleotide and nucleotide-protein BLAST 
search program.
Statistical analysis. The obtained results were an-
alyzed using non-parametric Pearson’s Chi-squared and 
Fisher’s exact tests as well as the Mann–Whitney U test 
Table 1. Comparison of results obtained by different methods used for the detection of human Beta-HPVs in 261 skin biopsies





nPCR vs. RHA universal probe 51 160 7 43 80.8% 0.58 (p=0.00)
nPCR vs. RHA totala 52 156 6 47 79.9% 0.57(p=0.00)
RHA universal probe vs. RHA 
specific probes 81 162 13 5 93.1%
0.85
(p=0.00)
HPV5 RHA genotyping vs. PCR 
spec. HPV5 8 248 2 3 98.1%
0.75
(p=0.00)
HPV8 RHA genotyping vs. PCR 
spec. HPV8 3 253 4 1 98.1%
0.56
(p=0.00)
nPCR vs. RHA EV-specific probesb 31 169 27 34 76.6% 0.35(p=0.000)
nPCR vs. RHA nonEV-specific 
probesc 27 188 31 15 82.4%
0.44
(p=0.000)
aresults of RHA with universal and specific probes; bRHA EV, specific probes for genotypes: HPV5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 
38, 49; cRHA nonEV, specific probes for genotypes: HPV47, 75, 76, 80, 92, 93, 96; EV, epidermodysplasia verruciformis
Figure 2. The spectrum and percentage of Beta-HPV genotypes in 86 samples assayed by RHA. 
Genotypes were classified into 5 different species according to Van Doorslaer et al., 2018
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to evaluate mixed-type Beta-HPV infections. In all of 
the above tests, the results were statistically significant at 
p<0.05. Pearson’s correlation coefficient value was cate-
gorized as follows: poor agreement (<0.20), fair agree-
ment (0.21–0.40), moderate agreement (0.41–0.60), good 
agreement (0.61–0.80), and very good agreement (>0.8). 
Statistical analysis was performed using the Statistica 
13.3 software.
RESULTS
All examined samples were positive for beta-actin, 
which confirmed their suitability for further analysis. The 
analytical sensitivity of nPCR with our modifications was 
determined as 100–1000 viral copies per reaction.
Overall, all the methods described above allowed 
for the detection of Beta-HPVs in 106 (41%) speci-
mens from 64 (54%) patients. Positive results were ob-
tained by nPCR and by RHA with the universal probe 
in 22.2% (58/261) and 36.0% (94/261) of samples, re-
spectively. These differences were statistically significant 
(Chi-squared test with Pearson’s modification, p<0.001). 
The agreement of these two methods was 80.8%. The 
sensitivity and specificity of nPCR compared to RHA 
with the universal probe were 54.2% and 95.8%, respec-
tively.
The use of PCR with specific primers for HPV5 and 
HPV8 enabled the detection of these viruses in 11 and 4 
samples, respectively, with two samples having both vi-
ruses at the same time. In 5 cases, the positive results 
did not coincide with nPCR.
In reverse hybridization, 99/261 (38%) samples were 
positive, of which in 86 samples the Beta-HPV geno-
types were identified, while in the further 13, only hy-
bridization with universal probes was observed. In 6 
specimens with a particular genotype (HPV38, 92 and 
93), simultaneous negative results with the universal 
probes were obtained. The results of the comparison 
of the above-mentioned methods were presented in 
Table 1.
The most frequently identified species was beta-1 (43% 
of all genotypes) followed by beta-2 (37%). The spectrum 
of genotypes in tumours and the perilesional area was pre-
sented in Fig. 2. In the 86 HPV-genotyped samples, 172 
genotypes were identified. The most frequently identified 
type was HPV23 (17 samples), followed by HPV93 and 
HPV24 (16 and 15 samples, respectively). The HPV47 
type was not found. A single genotype occurred in 47 
(54.6%) samples, while multiple infections with two or 
more skin HPVs (up to 8) were present in 39 samples 
(average 3.2±1.7 genotypes). The most common types 
found in co-infections were HPV23, 24 and 9.
Among the 261 specimens, 135 samples were col-
lected from the centre of tumours and 126 from perile-
sional skin without clinical changes. The analysis of these 
specimens demonstrated that there were no statistically 
significant differences between those two kinds of mate-
rial in positive results using nPCR and RHA with uni-
versal probes. The average number of genotypes in the 
samples taken from the tumour and from healthy skin 
was 2.1±1.7 and 1.9±1.4, respectively, and no significant 
differences in the occurrence of single and mixed in-
fections were observed (Mann–Whitney U test, p=0.8). 
Some differences were revealed only in the frequency of 
several HPV types, i.e.: HPV9, HPV12, HPV49, HPV92 
and HPV93, which appeared slightly more often in the 
biopsies from lesions than in those from healthy skin. 
Using all mentioned tests, half of 128 sample pairs (le-
sion/perilesional healthy area) had negative results, while 
in 31.2% of the examined pairs, the presence of Beta-
HPV DNA was confirmed in both samples. Divergent 
results were obtained for 24 pairs (in 17 of them HPV 
was detected only in the biopsies taken from the lesions 
and in 7 only in the biopsies from healthy skin).
Table 2. Results of direct sequencing of nPCR amplicons in 19 samples possible to analyse
Sequencing results Established types(>90% homology)
Related types
(75–90% homology) No. of detected genotypes
Types from the RHA panel 15 (60%) 89 (55%) 104 (56%)
Types from outside of the RHA panel 10 (40%) 72 (45%) 82 (44%)
Total 25 161 186
Table 3. Presentation of Beta-HPV types obtained by sequencing in five samples reacting only with the universal probe in RHA
Sample ID Established  Beta-HPV types
Related  
Beta-HPV types No. of detected types
No. of types from  
outside of the RHA-panel
10 124, 152 36 3 2
47 – 17, 20, 37, 110, 113, 122, 145, 174 8 5
162 20 21 2 –
230 15 9, 17, 38, 80, 110, 111, 113, 122, 145, 174 11 6
240 5, 36 24, 93, 98, 99, 105, 143 8 4
Total 6 26 32 17
The types from outside of the RHA-panel are in bold
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Results of nPCR amplicons sequencing
In total, 48 samples positive with the universal probe 
in RHA were subjected to sequencing. Only for 19 of 
those (39.6%) it was possible to determine the Beta-HPV 
genotype. According to Berkhout and others (Berkhout 
et al., 1995) and Surentheran and others (Surentheran et 
al., 1998), not only nucleotide but also amino acid se-
quences were used for the genotype assessment. If the 
sequence homology was above 90% compared to any 
known type, it was considered as an established type, 
while 75–90% homology meant the so-called “related 
type”. When comparing the obtained sequences to those 
available in the NCBI database, the presence of 25 types 
from the panel detected by RHA as well as the pres-
ence of types from outside the RHA panel but belong-
ing to the genus Betapapillomavirus was uncovered. The 
results of direct sequencing of nPCR amplicons were 
presented in Table 2. In these 19 biopsies analysed, 25 
established Beta-HPV genotypes were revealed. Among 
these, fifteen types represented the RHA panel (HPV5, 
8, 9, 12, 15, 20, 25, 36, 80). In 14 samples with geno-
types confirmed by RHA, the direct sequencing allowed 
detection of extra 13 genotypes, including 8 genotypes 
from outside of the RHA panel. Among the 161 related 
types, 55% represented types from the RHA panel. The 
most common ones were: HPV99, 110, 113, 122. Only 
in three out of 19 samples analysed, a single genotype 
was present (HPV25, HPV105 or HPV151).
In one case, 100% homology was observed between 
the analysed sequence and the corresponding reference 
HPV12 type.
Among the five samples positive only with the uni-
versal probe in RHA, 32 different Beta-HPV sequences 
were identified, including six established types (HPV5, 
15, 20, 36, 124, 152). In four of these samples, Beta-
HPVs from outside the panel were detected (Table 3).
Sequencing of eight samples positive for HPV5 by 
RHA confirmed the presence of this oncogenic type 
only in two cases (together with HPV36 and HPV143 
types). The presence of HPV8 was not confirmed in the 
amplicons sequenced.
DISCUSSION
Studies of the incidence of skin Beta-HPVs conduct-
ed in samples from patients with NMSC from different 
countries depend on the sensitivity and specificity of the 
methods used.
In the present study, we evaluated the molecular 
methods of determining the presence of Beta-HPVs in 
the skin from cancerous or precancerous lesions and 
from neighbouring clinically healthy skin. Based on the 
previous studies (Berkhout et al., 1995; Wieland et al., 
2000), freshly frozen biopsies were selected for the anal-
ysis. Our research began in 2006 and lasted for ten years, 
which allowed us to collect enough material to evaluate 
the methods used. The choice of the two-step nPCR 
method according to Berkhout et al. (1995) was dictat-
ed by a rather low amount of the virus in the changed 
tissues, as described by other authors (Stockfleth et al., 
2004; Wieland et al., 2000). Next methods used were the 
specific one-step PCRs for HPV5 and HPV8 and a nov-
el commercial test for genotyping. In the selected pool 
of specimens, the study was extended by direct sequenc-
ing of nPCR amplicons.
The detection threshold of the nPCR method used by 
us turned out to be similar to that given by Berkhout 
and others (Berkhout et al., 1995) and Meyer and others 
(Meyer et al., 2000). First, nPCR and hybridization with 
universal probes were compared. The nPCR proved to 
be significantly less sensitive than RHA at its relatively 
high specificity. This fact and only 80% agreement of 
these two tests possibly result from the amplification 
of a longer fragment of the DNA strand by nPCR than 
in RHA (374–389 bp and 117 bp, respectively) as well 
as the application of degenerate CP-primers for nPCR 
in contrast to RHA with nine nondegenerate primers. 
Other authors also pointed to such differences, e.g. in 
their study, Meyer and others (Meyer et al., 2000) un-
derlined the fact that the application of nondegener-
ate primers increases the sensitivity of the PCR. Simi-
lar results were reported by de Koning and others (de 
Koning et al., 2006), who emphasized statistically lower 
sensitivity of nPCR with slightly modified CP prim-
ers compared to RHA. Furthermore, nPCR detects 19 
types of Beta-HPVs, while RHA can also identify ad-
ditional types, such as HPV47, 75, 76, 80, 92, 93, 96. 
This fact also contributes to the underestimation of the 
results obtained with this nPCR method. To increase the 
possibility of HPV detection using PCR, other research 
groups employed several additional primer pairs (Meyer 
et al., 2000; Stockfleth et al., 2004), slight modifications 
in primer sequences or PCR conditions (Harwood et al., 
1999; Berkhout et al., 2000) as well as the application of 
primers derived from the viral E region (de Koning et 
al., 2006; Gheit et al., 2007).
In contrast to the previous reports (de Koning et al., 
2006; Bouwes Bavinck et al., 2010), by using the com-
mercial RHA test, we revealed the presence of Beta-
HPVs less often, because only in about 40% of the 
tested biopsies. These discrepancies may result from dif-
ferent clinical diagnosis and material used in the study 
(not only skin biopsies but also eyebrow hair), as well 
as different epidemiology of Beta-HPV infections in dif-
ferent geographic regions of the world. In our studies, 
in contrast to the ones mentioned above, in the group 
of patients diagnosed with NMSC, BCC dominated, not 
SCC.
Moreover, in 5% of the samples tested by the RHA, 
we obtained positive results only with universal probes 
without the identification of specific types. Mackintosh 
and others (Mackintosh et al., 2009) showed similar re-
sults in 13% of their examined samples. Such results in-
dicated the presence of unspecified genotypes (from out-
side of the tested panel) from the Beta-HPV species or, 
otherwise, too low viral load for genotyping. Obtaining 
HPV confirmations for types 38, 92 and 96 without a 
positive reaction with universal probes can be explained 
by the inactivity of these probes with the aforemen-
tioned types of virus, which was confirmed by de Kon-
ing and others (de Koning et al., 2006).
In the reports by Zakrzewska and others (Zakrzewska 
et al., 2012) and Mackintosh and others (Mackintosh et 
al., 2009), similarly to the current study, both beta-1 and 
beta-2 species predominated among the studied types. 
This fact is understandable due to the highest number 
of HPV types in these species. The profile of genotypes 
found in our studies is very similar to many earlier pub-
lications. The most common types, 23, 93 and 24, also 
occurred as dominant in the previous research (de Kon-
ing et al., 2009; Bouwes Bavinck et al., 2010).
In the majority of tests carried out with the RHA, the 
presence of HPV47 was not confirmed and similar nega-
tive results were also obtained in this study. Only Bou-
wes Bavinck and others (Bouwes Bavinck et al., 2010) 
and Zakrzewska and others (Zakrzewska et al., 2012) 
reported the presence of HPV47 in the tested material 
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from Southern Europe in a small (1–4%) share of all 
genotypes. Considering the high sensitivity of the RHA 
for HPV47 (10 copies per assay), according to de Kon-
ing and others (de Koning et al., 2006), the above fact 
can only be explained by the absence or very low load 
of HPV47 in the diagnostic samples.
The results obtained using reverse hybridization, re-
ported in all above-discussed studies, as well as our data, 
confirmed the frequent presence of mixed types of Beta-
HPVs in various clinical material tested.
Like other authors, we focused on two oncogenic 
Beta-HPV types. However, in contrast to most of the 
previous studies, there were few HPV5 or HPV8 iden-
tified in our study using not only specific PCR but also 
the RHA method. The most similar results using the 
RHA were obtained by Mackintosh and others (Mack-
intosh et al., 2009) who showed the presence of HPV5 
and HPV8 DNA in 6.8% and 2.5% of the biopsies 
analysed, respectively. In material collected mainly from 
BCC, Zakrzewska and others (Zakrzewska et al., 2012) 
confirmed the presence of both high-risk HPV types in 
18% and 10% of samples, respectively. Using nPCR with 
specific primers for HPV8, Pfister and others (Pfister et 
al., 2003) detected infections with this type in up to 60% 
of biopsies from the skin with pre-cancerous lesions in 
Polish patients. Comparing our results with the above-
quoted data, a rather low load of these oncogenic Beta-
HPVs in materials collected from our patients cannot 
be excluded. Therefore, the nPCR with specific primers, 
more sensitive than single-step PCR, seems to be more 
useful. Moreover, considering the large number of multi-
ple infections, underestimation of single types associated 
with a low load of their DNA may not be ruled out (de 
Koning et al., 2007).
The analysis of the results of direct sequencing was 
possible only in about 40% of the samples tested due 
to overlapping peaks in the obtained fluorogram, pos-
sibly indicating the presence of multiple HPV types in 
the samples assayed (Li et al., 2013). By the sequencing, 
additional types were shown, other than the ones de-
tected only by the hybridization method as in the report 
by Gheit and others (Gheit et al., 2007). Most of the 
sequences analysed yielded results indicating the pres-
ence of several types of Beta-HPV species, both from 
the RHA panel as well as from outside of this panel. In 
agreement with previously presented studies (de Koning 
et al., 2006; Gheit et al., 2007), the majority of analysed 
sequences indicated the presence of HPVs belonging to 
the beta-1 and beta-2 species. Sequencing of samples 
that showed a positive reaction only with the universal 
probes in RHA revealed the presence of not only types 
from outside of the RHA panel but also the presence 
of other types that should be detected by hybridization. 
The reason for this, which other authors also pointed 
out (Antonsson et al., 2013), might be too low load of 
individual types of viruses and the presence of viral co-
infections. In contrast to the RHA, among the analysed 
sequences, the presence of HPV type 47 was demon-
strated in two samples tested as the related type (75–
90% homology). The detection failures for RHA and 
sequencing of HPV5 and 8 might have been due to the 
missing certain types in direct sequencing of amplicons 
derived from broad-spectrum PCR (Forslund et al., 1999; 
Meyer et al., 2000). Given the low viral load in tissues 
with NMSC (one copy per 100–400 cells) (Weissenborn 
et al., 2009), only dominant types could be amplified and 
sequenced in samples with multiple Beta-HPV infections.
A significant spread of Beta-HPVs in the environment 
and in the skin, low viral load in the tissues, a large va-
riety of viral genotypes and high frequency of multiple 
infections justify the need to use not only sensitive but 
also specific methods for the detection of viral infec-
tions. On the other hand, the lack of adopted standardi-
zation rules, the use of methods of different sensitivity 
and primers of different specificity make it difficult and 
sometimes impossible to compare the obtained results. 
In the present work, the results of genotyping obtained 
by RHA were confirmed and extended to identify ad-
ditional types by the nPCR method with subsequent se-
quencing as well as the PCR with primers specific for 
potentially oncogenic Beta-HPV types. In our opinion, 
the statistically-supported compliance of all methods 
used for the detection and genotyping of Beta-HPVs 
turned out to be only moderate. In view of the above, as 
well as taking into account the results obtained, we are 
advocates of assessing the presence and dissemination 
of a viral infection by not only one detection method 
but by extending the diagnostic possibilities to use other 
methods.
Perhaps in the future, sensitive, established and stand-
ardized diagnostic methods will allow assessing the risk 
of developing cancer and contribute to the inclusion of 
prevention as well as targeted therapy to prevent Beta-
HPV-related cancers.
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